Specific-site methylation of tumour suppressor ANKRD11 in breast cancer

Sue Ping Lim, Nick C. Wong, Rachel J. Suetani, Kristen Ho, Jane Lee Ng, Paul M. Neilsen, Peter G. Gill, Raman Kumar, David F. Callen

Research output: Contribution to journalArticleResearchpeer-review

Abstract

ANKRD11 is a putative tumour suppressor gene in breast cancer, which has been shown in our laboratory to be a co-activator of p53. Our data suggest that down-regulation of ANKRD11 is associated with breast tumourigenesis. Breast cancer cell lines treated with DNA demethylating agents resulted in up-regulation of ANKRD11 expression suggesting that promoter DNA methylation may be responsible for its down-regulation. The transcriptional activity of a CpG-rich region 2 kb upstream of the transcription initiation site of ANKRD11 was investigated using dual-luciferase reporter assays. The constructs carrying -661 to -571 bp promoter sequence showed significant transcriptional activity. Using the SEQUENOM Epityper Platform, the region between -770 and +399 bp was analysed in 25 breast tumours, four normal breast tissues and five normal blood samples. The region between -770 and -323 bp was shown to be frequently methylated in breast tumours. The methylation patterns of all analysed CpGs in this region were identical in the normal and tumour samples, except for a 19 bp region containing three CpG sites. These sites had significantly higher levels of methylation in tumours (40%) compared to normal samples (6%). Our findings support the role of ANKRD11 as a tumour suppressor gene and suggest that aberrant DNA methylation of three CpGs in a 19 bp region within the ANKRD11 promoter may be responsible for its down-regulation in breast cancer.

Original languageEnglish
Pages (from-to)3300-3309
Number of pages10
JournalEuropean Journal of Cancer
Volume48
Issue number17
DOIs
Publication statusPublished - 1 Nov 2012
Externally publishedYes

Keywords

  • ANKRD11
  • Breast cancer
  • Decitabine
  • Promoter activity
  • SEQUENOM
  • Specific DNA methylation
  • Tumour suppressor
  • Zebularine

Cite this

Lim, S. P., Wong, N. C., Suetani, R. J., Ho, K., Ng, J. L., Neilsen, P. M., ... Callen, D. F. (2012). Specific-site methylation of tumour suppressor ANKRD11 in breast cancer. European Journal of Cancer, 48(17), 3300-3309. https://doi.org/10.1016/j.ejca.2012.03.023
Lim, Sue Ping ; Wong, Nick C. ; Suetani, Rachel J. ; Ho, Kristen ; Ng, Jane Lee ; Neilsen, Paul M. ; Gill, Peter G. ; Kumar, Raman ; Callen, David F. / Specific-site methylation of tumour suppressor ANKRD11 in breast cancer. In: European Journal of Cancer. 2012 ; Vol. 48, No. 17. pp. 3300-3309.
@article{ae3c7989ca1845f1bba12c2fda6c04a6,
title = "Specific-site methylation of tumour suppressor ANKRD11 in breast cancer",
abstract = "ANKRD11 is a putative tumour suppressor gene in breast cancer, which has been shown in our laboratory to be a co-activator of p53. Our data suggest that down-regulation of ANKRD11 is associated with breast tumourigenesis. Breast cancer cell lines treated with DNA demethylating agents resulted in up-regulation of ANKRD11 expression suggesting that promoter DNA methylation may be responsible for its down-regulation. The transcriptional activity of a CpG-rich region 2 kb upstream of the transcription initiation site of ANKRD11 was investigated using dual-luciferase reporter assays. The constructs carrying -661 to -571 bp promoter sequence showed significant transcriptional activity. Using the SEQUENOM Epityper Platform, the region between -770 and +399 bp was analysed in 25 breast tumours, four normal breast tissues and five normal blood samples. The region between -770 and -323 bp was shown to be frequently methylated in breast tumours. The methylation patterns of all analysed CpGs in this region were identical in the normal and tumour samples, except for a 19 bp region containing three CpG sites. These sites had significantly higher levels of methylation in tumours (40{\%}) compared to normal samples (6{\%}). Our findings support the role of ANKRD11 as a tumour suppressor gene and suggest that aberrant DNA methylation of three CpGs in a 19 bp region within the ANKRD11 promoter may be responsible for its down-regulation in breast cancer.",
keywords = "ANKRD11, Breast cancer, Decitabine, Promoter activity, SEQUENOM, Specific DNA methylation, Tumour suppressor, Zebularine",
author = "Lim, {Sue Ping} and Wong, {Nick C.} and Suetani, {Rachel J.} and Kristen Ho and Ng, {Jane Lee} and Neilsen, {Paul M.} and Gill, {Peter G.} and Raman Kumar and Callen, {David F.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.ejca.2012.03.023",
language = "English",
volume = "48",
pages = "3300--3309",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier",
number = "17",

}

Lim, SP, Wong, NC, Suetani, RJ, Ho, K, Ng, JL, Neilsen, PM, Gill, PG, Kumar, R & Callen, DF 2012, 'Specific-site methylation of tumour suppressor ANKRD11 in breast cancer', European Journal of Cancer, vol. 48, no. 17, pp. 3300-3309. https://doi.org/10.1016/j.ejca.2012.03.023

Specific-site methylation of tumour suppressor ANKRD11 in breast cancer. / Lim, Sue Ping; Wong, Nick C.; Suetani, Rachel J.; Ho, Kristen; Ng, Jane Lee; Neilsen, Paul M.; Gill, Peter G.; Kumar, Raman; Callen, David F.

In: European Journal of Cancer, Vol. 48, No. 17, 01.11.2012, p. 3300-3309.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Specific-site methylation of tumour suppressor ANKRD11 in breast cancer

AU - Lim, Sue Ping

AU - Wong, Nick C.

AU - Suetani, Rachel J.

AU - Ho, Kristen

AU - Ng, Jane Lee

AU - Neilsen, Paul M.

AU - Gill, Peter G.

AU - Kumar, Raman

AU - Callen, David F.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - ANKRD11 is a putative tumour suppressor gene in breast cancer, which has been shown in our laboratory to be a co-activator of p53. Our data suggest that down-regulation of ANKRD11 is associated with breast tumourigenesis. Breast cancer cell lines treated with DNA demethylating agents resulted in up-regulation of ANKRD11 expression suggesting that promoter DNA methylation may be responsible for its down-regulation. The transcriptional activity of a CpG-rich region 2 kb upstream of the transcription initiation site of ANKRD11 was investigated using dual-luciferase reporter assays. The constructs carrying -661 to -571 bp promoter sequence showed significant transcriptional activity. Using the SEQUENOM Epityper Platform, the region between -770 and +399 bp was analysed in 25 breast tumours, four normal breast tissues and five normal blood samples. The region between -770 and -323 bp was shown to be frequently methylated in breast tumours. The methylation patterns of all analysed CpGs in this region were identical in the normal and tumour samples, except for a 19 bp region containing three CpG sites. These sites had significantly higher levels of methylation in tumours (40%) compared to normal samples (6%). Our findings support the role of ANKRD11 as a tumour suppressor gene and suggest that aberrant DNA methylation of three CpGs in a 19 bp region within the ANKRD11 promoter may be responsible for its down-regulation in breast cancer.

AB - ANKRD11 is a putative tumour suppressor gene in breast cancer, which has been shown in our laboratory to be a co-activator of p53. Our data suggest that down-regulation of ANKRD11 is associated with breast tumourigenesis. Breast cancer cell lines treated with DNA demethylating agents resulted in up-regulation of ANKRD11 expression suggesting that promoter DNA methylation may be responsible for its down-regulation. The transcriptional activity of a CpG-rich region 2 kb upstream of the transcription initiation site of ANKRD11 was investigated using dual-luciferase reporter assays. The constructs carrying -661 to -571 bp promoter sequence showed significant transcriptional activity. Using the SEQUENOM Epityper Platform, the region between -770 and +399 bp was analysed in 25 breast tumours, four normal breast tissues and five normal blood samples. The region between -770 and -323 bp was shown to be frequently methylated in breast tumours. The methylation patterns of all analysed CpGs in this region were identical in the normal and tumour samples, except for a 19 bp region containing three CpG sites. These sites had significantly higher levels of methylation in tumours (40%) compared to normal samples (6%). Our findings support the role of ANKRD11 as a tumour suppressor gene and suggest that aberrant DNA methylation of three CpGs in a 19 bp region within the ANKRD11 promoter may be responsible for its down-regulation in breast cancer.

KW - ANKRD11

KW - Breast cancer

KW - Decitabine

KW - Promoter activity

KW - SEQUENOM

KW - Specific DNA methylation

KW - Tumour suppressor

KW - Zebularine

UR - http://www.scopus.com/inward/record.url?scp=84868199867&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.03.023

DO - 10.1016/j.ejca.2012.03.023

M3 - Article

VL - 48

SP - 3300

EP - 3309

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -